Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Waldenstrom Macroglobulinemia Clinical Trials

A listing of Waldenstrom Macroglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (8) clinical trials

Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies

This study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying ...


A clinical trial seeking patients for a research study for the treatment of Waldenstrom's Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Lymphoma, Mixed Lymphoproliferative Disease

Background Persons may be prone to develop hematologic or lymphoproliferative cancer for a variety of reasons including: inherited predisposition of benign, premalignant, or malignant conditions; environmental exposures shared by family members; previous tumors or preneoplastic conditions; immune deficiency; or stochastic processes Investigations of individuals and families at high risk of ...

Phase N/A

A clinical trial to evaluate treatments for patients with Chronic Myelomonocytic Leukemia in Remission, Graft-Versus-Host Disease, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Multiple Myeloma, Acute Myeloid Leukemia in Remission, Waldenstrom's Macroglobulinemia, Severe Aplastic Anemia, Hodgkin's Disease, MYELODYSPLASTIC SYNDROME, Minimal Residual Disease, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission

PRIMARY OBJECTIVES: I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. SECONDARY OBJECTIVES: I. To evaluate clinical response, ...


Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...


A clinical trial seeking patients for a research study for the treatment of Waldenstrom's Macroglobulinemia, Lymphoma, Multiple Myeloma, Myeloid Leukemia, MYELODYSPLASTIC SYNDROME, Lymphoid leukemia, Myelosclerosis with myeloid metaplasia, Preleukemia

This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant. A pilot clinical trial to characterize the incidence, prevalence and function of myeloid-derived suppressor cells (MDSCs) and immune checkpoint regulators (V-domain Ig Suppressor of T-cell Activation [VISTA], cytotoxic T-lymphocyte- associated ...


Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of entospletinib administered in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), and identify the dose for phase 2 expansion. (Phase I) II. To evaluate the efficacy of entospletinib in combination with ...


A clinical trial seeking patients for a research study for the treatment of Waldenstrom's Macroglobulinemia, Lymphoma

The Study Vaccine: The cancer vaccine used in this study is made from DNA (the genetic material of cells). The vaccine is designed to increase your immune system's ability to react against lymphoplasmacytic lymphoma. Making the Vaccine: About 12 months are needed to make this vaccine from your tumor. Although ...


A clinical trial seeking patients for a research study of Idelalisib, Obinutuzumab

An Open Label non-randomized Phase II Study exploring chemo-free treatment association with Idelalisib and Obinutuzumab in Patient with relapsed refractory Waldenstrom's Macroglobulinemia